Jefferies Group LLC reiterated their hold rating on shares of Cempra, Inc. (NASDAQ:CEMP) in a report released on Thursday. The brokerage currently has a $3.00 price target on the biotechnology company’s stock.
CEMP has been the subject of several other reports. Zacks Investment Research upgraded Cempra from a hold rating to a buy rating and set a $3.50 price target for the company in a research note on Friday, August 11th. Stifel Nicolaus restated a hold rating and issued a $4.00 price target on shares of Cempra in a research note on Thursday, August 10th. ValuEngine downgraded Cempra from a sell rating to a strong sell rating in a research note on Friday, June 2nd. Finally, Roth Capital downgraded Cempra from a buy rating to a neutral rating and reduced their price target for the company from $8.00 to $4.00 in a research note on Thursday, August 10th. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $10.00.
Cempra (NASDAQ CEMP) remained flat at $3.10 during midday trading on Thursday. 1,675,366 shares of the company traded hands. The stock has a 50-day moving average price of $3.23 and a 200-day moving average price of $3.80. The company’s market capitalization is $162.77 million. Cempra has a 12-month low of $2.55 and a 12-month high of $26.95.
Cempra (NASDAQ:CEMP) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The company had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period in the previous year, the company posted ($0.51) EPS. The firm’s revenue for the quarter was down 74.9% compared to the same quarter last year. Equities analysts predict that Cempra will post ($1.01) EPS for the current year.
Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its position in shares of Cempra by 5.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 39,499 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 1,870 shares during the period. Teachers Advisors LLC lifted its position in shares of Cempra by 5.2% during the 4th quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock valued at $262,000 after acquiring an additional 4,632 shares during the period. Voya Investment Management LLC lifted its position in shares of Cempra by 34.1% during the 2nd quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 5,848 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Cempra by 35.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 6,800 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Cempra by 1.3% during the 2nd quarter. Northern Trust Corp now owns 546,294 shares of the biotechnology company’s stock valued at $2,513,000 after acquiring an additional 6,846 shares during the period. Hedge funds and other institutional investors own 49.76% of the company’s stock.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.